Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis
Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II
  • Phase

    Phase 3
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

The purpose of this study is to investigate the efficacy of LAS41005 in comparison to placebo and to LAS106521 in actinic keratosis (AK).
To investigate as primary objective:

Superiority to placebo and non-inferiority to LAS106521 measured by histological clearance of one predefined target lesion;

To investigate as secondary objective:

Superiority to LAS106521
Improvement of treated lesions (lesion response)
Assessment of tolerability and safety by physicians global assessment score (PGA, PGT)
Patient's assessment of tolerability and efficacy and patient's compliance
Study Started
Jun 30
Primary Completion
Jun 30
Study Completion
Jun 30
Last Update
Jul 28

Drug Placebo Gel


Drug LAS41005


Drug LAS106521


Placebo Placebo Comparator

LAS41005 Experimental

LAS106521 Active Comparator


Main Inclusion Criteria:

Have at least 4 but not more than 10 clinically confirmed AK target lesions of mild to moderate intensity within the face/forehead or bald scalp (excluding eyelids, lips, and mucosa), i.e. actinic keratosis grade I and II according to Olsen EA et al. 1991
Woman of childbearing potential are allowed to participate in this study only if they use a highly effective method of contraception

Main Exclusion Criteria:

Have received effective treatment of AK in the three months preceding this clinical trial
Have known hypersensitivity to LAS41005 or LAS106521
Have currently other malignant or benign tumors of the skin within the treatment area (e.g. malignant melanoma, basal cell carcinoma, squamous cell carcinoma)
Patient's taking phenytoin
Show cornu cutaneum like alterations of the skin in the face or the bald scalp (target area)
No Results Posted